2012 Fiscal Year Final Research Report
Randomized controlled trial of the second generation antipsychotics for the schizophrenia individualization treatment algorithm.
| Project/Area Number |
23791357
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Kansai Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KINOSHITA Toshihiko 関西医科大学, 医学部, 教授 (20186290)
OKUGAWA Gaku 関西医科大学, 医学部, 准教授 (80343672)
KATO Masaki 関西医科大学, 医学部, 講師 (00351510)
AZUMA Junichi 兵庫医療大学, 薬学部, 教授 (30144463)
NONEN Shinpei 兵庫医療大学, 薬学部, 講師 (40467527)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Keywords | 精神薬理学 / 臨床精神分子遺伝学 / 老年精神医学 / リエゾン精神医学 |
|---|
| Research Abstract |
To evaluate the efficacy and safety of aripiprazole and perospirone in Japanese patients with schizophrenia. In this 12-week, randomized, flexible-dose, open-label study, patients diagnosed with schizophrenia were randomized to receive aripiprazole (3-30mg/day, n=49) or perospirone (8-48mg/day, n=51). Both groups showed significant improvements during the study, with reductions in the total PANSS scores (Repeated measure analysis of variance, both p<0.0001). There were no significant differences in the PANSS change scores, CGI-S change scores, DIEPSS total score, BAS total score or over time between groups.
|
